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Core-Shell Functionalized Zirconium-Pemetrexed
Coordination Nanoparticles as Carriers with a High Drug
Content
Benjamin Steinborn, Patrick Hirschle, Miriam Höhn, Tobias Bauer, Matthias Barz,
Stefan Wuttke, Ernst Wagner, and Ulrich Lächelt*
Selected drug molecules with Lewis base functions can be assembled into
coordinative nanoparticles (NPs) by linking them with suitable metal ions.
Such nanomaterials exhibit a high material economy due to high drug
contents and minor amounts of inactive additives. The antifolate pemetrexed
(PMX) which is used for the treatment of lung cancers contains two carboxy
functions that are able to undergo coordinative binding of metal ions. This
study presents the development of a multilayer PMX NP system where each
layer serves a distinct purpose. The metal-drug NP core is assembled in a
bottom-up approach by coordinative interactions between zirconium (IV) ions
and PMX molecules. Since the NP core is generated from drug molecules as
essential units, it features a very high drug content of almost 80%. The NP
core is stabilized against serum with a shell of a polymerized
oligoamine-modiﬁed trimethoxysilane derivative (TMSP). As external layer, a
polyglutamate-block-polysarcosine-N3 (pGlu-b-pSar) coating mediates
eﬃcient colloidal stabilization and enables introduction of targeting
functionalities by click chemistry. Attaching folate or transferrin ligands to the
polymer layer enhances NP uptake into target receptor positive KB and L1210
cells. This study illustrates the development and characterization of
metal-drug coordination NPs with high drug content and variable external
functionalizations.
1. Introduction
Pharmacokinetic properties are inherent characteristics of drug
molecules that cannot be changed without derivatization.
Nanoparticles (NPs) which are small enough to circulate in the
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bloodstream and carry cargo molecules are
attractive materials for the utilization as
drug containers since their pharmacoki-
netic properties can be tuned without aﬀect-
ing the pharmacodynamics of the drug. NP
drug delivery systems are therefore being
investigated to overcome the poor selectiv-
ity and major side eﬀects frequently asso-
ciated with chemotherapy.[1] Conventional
chemotherapy often suﬀers from unfavor-
able pharmacokinetics, limited tumor accu-
mulation, and systemic toxicity. As a con-
sequence, high doses are required for eﬃ-
cient tumor treatment but the severe dose-
limiting oﬀ-target eﬀects determine a nar-
row therapeutic window and impair pa-
tient beneﬁts in the clinical practice.[2] Re-
cent approaches in nanotechnology work
toward ameliorating the situation by de-
veloping chemotherapeutic NP formula-
tions aimed at increasing drug selectiv-
ity toward neoplastic tissues by employing
active and passive targeting strategies of
single or combination therapies[3] and en-
hancing therapeutic indices.[4] At present,
about 40 nanomedicines,[5] for instance
liposomal doxorubicin[6] and iron-oxide NP formulations,[7] are
used for a variety of indications. Recently, highly regular coor-
dination polymers such as metal-organic frameworks[8] (MOFs)
have emerged as an additional class of nanomaterials.[9] Sev-
eral MOFs utilize polydentate carboxylic acid linkers and their
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coordinative interactions with metal ions to obtain deﬁned crys-
talline structures. As MOFs span a rich chemical space of
about 70 000 reported structures[10] with varying degrees of
porosity[8b,11] and tailorable sizes,[12] they are mainly explored for
catalysis,[13] gas storage,[14] separation,[15] sensing,[16] and drug
delivery[3,17] applications. However, delivering small molecule
drugs by encapsulation into MOF pores is not trivial and de-
pending on the used drug and MOF, the drug content varies
signiﬁcantly.[17g] High drug loading is generally a desired pa-
rameter of drug delivery systems in order to minimize expo-
sure of patients to nanocarrier material and reduce possible
adverse reactions. Moreover, the aim of a high drug to car-
rier ratio corresponds to the modern concepts of “atom econ-
omy” and “multifunctional eﬃciency” in the context of NPs.[18]
Hypothetical nanopharmaceuticals with the highest imaginable
drug to carrier ratio and most simple synthesis would be com-
posed of drug molecules only which assemble into NPs them-
selves. On the other hand, conventional therapeutic agents me-
diate their pharmacological eﬀect in a dissolved state and a dy-
namic conversion from stable drug colloids to solubilized drug
molecules is required. In general, native drug molecules do
not fulﬁll these requirements. Approximations of these envi-
sioned ideal nanopharmaceuticals are represented bymetal-drug
NPs. By replacing the pharmacologically inactive linkers typically
used to synthesize MOFs with polydentate carboxy-containing
or phosphate-modiﬁed active pharmaceutical ingredients, for in-
stance, disuccinatocisplatin,[19] acetaminophen phosphate,[20] or
methotrexate,[21] coordination polymers with higher drug con-
tents and multifunctional eﬃciencies are feasible. However, in
many cases such structures seem to exhibit limited physiological
stabilities and require further stabilizing surfacemodiﬁcations as
observed and addressed by Rieter et al.[19b] and Huxford et al.[21]
Here, we report the development of a novel hybrid coordi-
native NP (Zr-PMX NP) based on zirconium ions (Zr4+) and
pemetrexed (PMX), an antifolate drug used for lung cancer
pharmacotherapy.[22] The aim of the study was the generation of
metal-drug nanopharmaceuticals with a high drug loading capac-
ity, favorable colloidal stability, the possibility for modiﬁcation
with receptor ligands and preserved pharmacological activity of
the drug. The Zr-PMX core with a very high drug content was
sequentially modiﬁed with silica and polymer shells in order to
achieve suitable serum and colloidal stabilities and allow for the
introduction of targeting ligands. The presented strategy for the
assembly of a multifunctional nanopharmaceutical with a very
high drug content is considered to be a versatile platform trans-
latable to other drugmolecules with functional groups capable of
coordinative interaction with metal ions.
2. Results
2.1. Development and Characterization of the Zr-PMX NP Core
Scheme 1 provides an overview of the sequential assembly of
multifunctional Zr-PMX NPs. First, the drug-containing NP
core is generated using the synthetic parameters described in
Scheme 1A. Scheme 1B depicts the addition of a silica layer to
enhance the NP core stability. The external silica surface is ﬁnally
coated with a polyglutamate-block-polysarcosine block copolymer
for simultaneous colloidal stabilization, sterical shielding, and
attachment of targeting ligands as illustrated in Scheme 1C.
Dynamic light scattering (DLS) measurements of the ﬁnal
formulations conﬁrming the assembly of NPs are depicted in
Figure S1, Supporting Information. Zirconium(IV) was chosen
as the metal component for the assembly of the drug containing
NP core due to its ability to form stable metal-organic complexes
with suitable biological tolerability as observed before with other
Zr-based MOFs and drug delivery systems.[23] The particles were
formed at room temperature within 45 min in an ethanol-water
mixture containing HCl and 100 equivalent formic acid as
additives for control of particle growth. The optimal linker:metal
ratio varies upon diﬀerent Zr-based metal-organic nanomateri-
als, such as 1:1[24] or 3:1,[20,25] therefore a range of PMX to Zr
stoichiometries was initially screened in this study. A molar
excess of PMX is favorable in terms of lower polydispersity
indices (PDIs), as observed for 3:1 and 3:2 ratios compared
to equimolar 3:3 (Figure S2, Supporting Information) with
z-averages between 130 and 220 nm. In case of excessive Zr at a
3:6 ratio, only minor particle formation could be observed within
the 45 min reaction time (Figure S1, Supporting Information).
A possible explanation lies within a higher number of initially
formed crystal nuclei which results in the NP growth being dis-
tributed over more individual particles leading to slower growth
of single particles as described by Wang et al.[26] Satisfactory
PDI and particle yield were achieved at a 3:1 PMX to Zr ratio
and these conditions were used for subsequent studies. In order
to generate particles within the nanometer size range suitable
for biological applications,[27] acid was added to the reaction
mixture. For samples without any acidiﬁcation, rapid clouding
and formation of particles in the micrometer range were ob-
served. By adding 100 equivalents formic acid, a monodentate
modulator also used for MOF synthesis,[24b,28] this immediate
aggregation was prevented and the particle formation occurred
more slowly (Figure S3, Supporting Information). Additional
HCl had a minor inﬂuence on size and PDI (Figure S4, Sup-
porting Information). Sonication of the obtained NPs mediated
favorable eﬀects on the particle size by disaggregating agglomer-
ates formed during the centrifugation and washing steps (Figure
S5, Supporting Information). The overall eﬀect of sonication
was about 100 nm of size decrease and 5 min of sonication was
determined to be suﬃcient, longer durations did not mediate
a further improvement. We found that the ﬂuorescent dye
calcein, which contains several Lewis base functions and forms
chelates with metal ions, can be co-assembled into the NP core.
Notably, the addition of 5% calcein only had a minor inﬂuence
on z-average and PDI (Figure S6, Supporting Information) and
enables ﬂuorescence-based detection by confocal microscopy or
ﬂow cytometry studies without the requirement for additional
labeling. Moreover, this illustrates the ﬂexibility of the presented
particle assembly concept and the possibility to encapsulate dif-
ferent cargos. We further investigated the NP core (Scheme 1A)
with regard to its physicochemical properties (Figure 1). Analysis
by scanning-electron microscopy (SEM, Figure 1A) revealed a
particle diameter of 64.26 ± 10.09 nm (n = 100).
The diﬀerence in size compared to the previously presented
DLS data can be attributed to the individual techniques, SEM-
imagingmeasures particles in dry formwhereas DLS determines
their hydrodynamic diameter in solution.[29] Energy dispersive
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Scheme 1. Overview of the utilized core-shell nanoparticle (NP) assembly approach. A) Synthesis of the drug-containing NP core and labeling by
coordinative integration of ﬂuorescent calcein dye; B) stabilization of the NP core by a polymerized silica shell; and C) simultaneous shielding and
targeting by coating with polyglutamate-polysarcosine block copolymers.
X-ray spectroscopy (Figure 1B) conﬁrmed the presence of key
elements, oxygen and carbon as part of the PMX structure and
zirconium as well as chloride due to the used metal compound
and the added HCl. The carbon signal can also be partially at-
tributed to the conductive carbon layer added during SEM sam-
ple preparation. X-ray diﬀraction (XRD) (Figure 1C) did not show
crystallinity, which is why we assume an amorphous structure of
Zr-PMXNPs. The porosity and surface area of the driedNPswere
investigated using nitrogen sorption (Figure 1D). Evaluating the
sorption isotherms with the BET method,[30] resulted in a sur-
face area of 170 m² g−1, suggesting porosity in the sample. Both
the nitrogen sorption isotherm and the corresponding pore size
distribution indicate this porosity stems mainly frommesopores
starting at 40 Å. Next, the PMX to Zrmass ratio present in the NP
core was determined (Figure 1E) by inductively coupled plasma
atom emission spectrometry (ICP-AES) and high-performance
liquid chromatography (HPLC). ICP-AES revealed a Zr content
of 20.03 ± 0.96% (m/m, n = 3). NP lysis followed by PMX quan-
tiﬁcation by HPLC showed a PMX content of 78.23 ± 1.83%
(m/m, n = 3). Similarly high drug contents have been observed
by Heck et al. for other zirconium-based drug formulations.[20,31]
Considering the Zr(IV) coordination number of six and two co-
ordinatively active carboxy functions per PMX molecule, our ob-
tained result is close to the hypothetical PMX to Zr ratio of 3 and
also corresponds to the feed ratio during NP synthesis. For Zr-
PMX NP, thermogravimetric analysis indicated a residual parti-
cle mass of 33.85% (Figure 1F). As the NP sample was heated in
a mixed N2/O2 atmosphere, which led to the formation of ZrO2,
the actual metal content is lower. By excluding the oxide forma-
tion (MWZrO2 = 123.22 gmol−1, MWZr= 91.22 gmol−1, factor:
1.35), the amount of non-oxidized Zr present in the NP can be
estimated as 33.85%/1.35 = 25.05%, which diﬀers only slightly
from the result determined by ICP–AES and also agrees very
well with the hypothetical particle composition. Next, the long-
term stability of as-synthesized NPs (Figure 1G) was evaluated in
ethanol (EtOH) at room temperature by performing DLS mea-
surements every 24 h. After 48 h, a minor increase in z-average
was observed whereas the PDI remained unchanged over 96 h.
As a precaution, the freshly prepared NPs were thus stored for a
maximum of 24 h for all experiments.
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Figure 1. Physiochemical characterization of the NP core containing the drug payload. A) Imaging by scanning-electron microscopy; B) qualitative
elemental composition determined by energy dispersive X-ray spectroscopy; C) analysis of crystallinity by X-ray diﬀraction; D) measurement of poros-
ity by nitrogen sorption analysis; E) particle composition by ICP–AES and HPLC (mean, n = 3); F) thermogravimetric analysis; and G) particle size,
polydispersity and stability in ethanol by dynamic light scattering (mean ± SD, n = 3).
2.2. Silica coating of Zr-PMX NP Cores Enhances their Serum
Stability and Uptake into Cancer Cells
Initial exploratory serum stability studies of the as-synthesized
Zr-PMX NP core revealed a high PMX release within 30 min
of serum incubation. In order to increase and control the
stability, we developed and applied a silica coating strategy
to the nanosystem. Although tetraethylorthosilicate (TEOS)
is commonly used for silica coatings,[32] this study utilized
N1-(3-trimethoxysilylpropyl)diethylenetriamine (TMSP) instead,
which has, to the best of our knowledge, only been previously
employed as a silica coating agent in a physicochemical setting[33]
but not for a biological or drug delivery application. Coating
NPs with a silica shell based on TEOS by applying the Stöber
method[34] typically requires an interfacing step by attaching a
polymer, such as poly-(vinylpyrrolidone) (PVP), to the NP surface
in order to maintain colloidal NP stability under the conditions
of the Stöber process.[32b,35] However, such a step introduces
additional complexity to the system and the used type of PVP
determines the ﬁnal particle characteristics.[35] Liz-Marzán et al.
directly coated gold NPs using (3-aminopropyl)trimethoxysilane
as the interfacing agent before applying the Stöber method to
deposit an additional TEOS layer.[36] This inspired us to use
TMSP which we perceived as even more suitable compared to
(3-aminopropyl)trimethoxysilane due to its diethylenetriamine
motif providing additional interaction sites for coordinative
and/or electrostatic attachment to the surface of Zr-PMX NPs
(Scheme 1B). As shown in Figure 2, we screened the inﬂu-
ence of the used TMSP amount and coating duration by DLS
(Figure 2A) and then proceeded to further characterize the
obtained Zr-PMX@TMSP NPs by SEM, energy dispersive x-ray
spectroscopy (EDX), and XRD.
Interestingly, coating times up to 5 h with the highest tested
TMSP amount of 3 µL resulted in small NPs and similar PDI
values whereas 24 h of coating with TMSP amounts of 1.5 µL or
higher resulted in strong particle aggregation and increased poly-
dispersity. The coating process mediated a distinct zeta potential
inversion from−20.8± 0.6mV to 25.9± 1.1mV or higher, which
did not change further after 5 h of coating time. After perform-
ing an aqueous wash to remove silica polymerization by-products
(Figure S7, Supporting Information), SEM-imaging (Figure 2B)
indicated a silica-coated NP size of 74.57 ± 16.64 nm (n = 100),
which implies an increase in diameter of approximately 10 nm
compared to the uncoated NP core and, thus, a silica shell thick-
ness of about 5 nm. Besides the increase in size and the ob-
served zeta potential inversion, EDX analysis (Figure 2C) also
conﬁrmed the presence of a silica peak. XRD analysis (Figure 2D)
revealed an additional peak at a 2-𝜃 of approximately 25° which
can be attributed to polymerized TMSP; a control spectrum of
polymerized TMSP without NPs (Figure S8, Supporting Infor-
mation) conﬁrms this suggestion. Next, the eﬀects of the sil-
ica coating on the serum stability were evaluated in a time- and
dose-dependent manner (Figure 3). Here, a distinct eﬀect of the
TMSP amount on the PMX release in serum (Figure 3A) was
observed.
After 30 min of incubation in 10% fetal bovine serum (FBS),
approximately 70% of the incorporated PMX was released from
the uncoated NPs. Coating with 1.5 µL TMSP reduced the release
to approximately 50% independent of the coating duration. The
stabilizing eﬀect was further increased with 3 µL TMSP. Here,
the observed PMX release was reduced to approximately 25%.
In all cases, the coating duration had a minor eﬀect on the
serum stability. We hypothesize that the TMSP layer stabilizes
the NP core by impairing the interaction between PMX and
serum protein. PMX is known to exhibit a high degree of
protein binding[37] which might compete with the coordinative
zirconium interactions that mediate formation of the NP core.
Higher amounts of TMSP are likely to further enhance the
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Figure 2. Characterization of the silica coating. A) Eﬀects of TMSP amount and coating duration on particle size determined by dynamic light scattering
(mean ± SD, n = 3); B) imaging of the silica-coated NPs by scanning-electron microscopy; C) qualitative elemental analysis by energy dispersive X-ray
spectroscopy and D) evaluation of crystallinity by X-ray diﬀraction.
stability. However, since the drug mediates its activity in a
solubilized state and has to be released from the nanocolloids,
we considered the achieved TMSP eﬀect to represent a suitable
balance between required stability and lability. Next, the eﬀect of
the TMSP-coating on the uptake of calcein-containing Zr-PMX
NP cores was evaluated on adherent A549 (human lung adeno-
carcinoma, Figure 3B) and L1210 (mouse lymphocytic leukemia
Figure 3C) suspension cell lines using confocal laser scanning
microscopy (CLSM). For both cell lines, the coating increased the
overall NP uptake, likely due to the increased serum stability and
the zeta inversion resulting in enhanced unspeciﬁc electrostatic
uptake as described for other nanosystems.[38] This observation
was additionally conﬁrmed using human cervix carcinoma KB
cells and quantiﬁed by ﬂow cytometry (Figure S9, Supporting
Information). TMSP-coated Zr-PMX NPs mediated signiﬁcantly
higher median calcein ﬂuorescence compared to uncoated NPs
or free calcein. The CLSM studies however revealed an external
NP attachment to the cell membrane and extracellular aggrega-
tion, which illustrated the need for further colloidal stabilization
in a biological environment. Since increased colloidal stability of
Zr-based MOFs has been achieved with a polyglutamate-block-
polysarcosine copolymer before,[39] we intended to adapt this
strategy to Zr-PMX@TMSP NPs.
2.3. Coating Zr-PMX@TMSP NPs with pGlu-b-pSar Mediates
Eﬃcient Shielding
In order to enhance the colloidal stability of Zr-PMX@TMSP
NPs, a sterical shielding was implemented by surface coating
with a polyglutamate31-polysarcosine160-N3 (pGlu-b-pSar) block
copolymer.[40] It has been shown in previous studies with Zr-
fum NPs that the polyglutamate block serves as the NP binding
and surface attachment module while the polysarcosine block
mediates eﬃcient shielding, colloidal stabilization, and preven-
tion of protein interactions.[39,41] Additionally, Finsinger et al. re-
ported steric stabilization and reduced complement activation
for a cationic nanostructure coated with an anionic PEG-derived
copolymer.[42] In order to stabilize our Zr-PMX@TMSP NPs,
an initial dose titration experiment was carried out by mixing
equal amounts of Zr-PMX@TMSP NPs with diﬀerent amounts
of pGlu-b-pSar (Figure 4).
Adding 500 µL of NP in HEPES-buﬀered glucose (HBG) to up
to 50 µg of polymer did not notably inﬂuence its z-average and
PDI but a zeta potential reduction depending on the polymer
dose was observed (Figure 4B). Zr-PMX@TMSP NPs without
pGlu-b-pSar coating exhibited a zeta potential of 28.73± 1.55mV,
which was reduced to 1.19 ± 0.06 mV by addition of 25 µg pGlu-
b-pSar. Increasing the amount of oﬀered polymer did not result
in a further zeta potential reduction, we therefore concluded
that 25 µg pGlu-b-pSar was suﬃcient to induce the observed
zeta potential shift toward neutrality, which is known to beneﬁt
NPs by reducing unspeciﬁc uptake, immune recognition, and
prolonging circulation half-lives.[38a,43] Next, we investigated how
the pGlu-b-pSar coating inﬂuenced the colloidal NP stability
at 37 °C. Incubating uncoated Zr-PMX@TMSP NPs in HBG
(Figure 4C) led to increasing aggregation over time; after 96
h the z-average almost doubled and a slight increase in PDI
was observed. In contrast, the pGlu-b-pSar-coated NPs did not
increase in size, retained their neutral zeta potential and showed
no diﬀerence in PDI over 96 h. The colloidal stability was also
evaluated in phosphate-buﬀered saline (PBS, Figure 4D) which
is a relevant biological buﬀer and challenging due to the strong
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Figure 3. The silica coating enhances the serum stability and promotes
NP uptake into cancer cells. A) Serum stability of TMSP-coated NPs de-
termined by HPLC (mean ± SD, n = 3); B) eﬀects of the coating on NP
uptake into adherent A549 lung adenocarcinoma or (C) suspension L1210
leukemia cells visualized by CLSM. Green, NP core labeled by coordinative
integration of calcein; Red, actin stained with phalloidin-rhodamine; Blue,
nuclei stained with DAPI.
interaction between phosphate and zirconium ions.[20,31,44] In-
deed, the uncoated NPs immediately aggregated to agglomerates
in the micrometer range and the sizes further increased over
time. In contrast, no increase in size or PDI was observed for
the pGlu-b-pSar coated Zr-PMX@TMSP NPs during 96 h of
incubation in PBS which illustrated the enormous colloidal
stabilization induced by the polymer coating. We also investi-
gated if the polymer remained attached to the NP surface under
serum-containing cell culture conditions (Figure 4E) since one
could expect competition between the polymer and negatively
charged serum protein for binding to the positively charged silica
shell. The azide-containing pGlu-b-pSar block copolymer was
therefore labeled with DBCO-Alexaﬂuor647 via strain-promoted
alkyne-azide cycloaddition (SPAAC). We then proceeded to
incubate calcein-containing Zr-PMX@TMSP NPs coated with
pGlu-b-pSar-AF647 on KB cells. After a total of 4 h incubation,
confocal microscopy showed yellow signals in themerge channel
which indicated co-localization between the calcein integrated
into the NP core (green channel) and the AF647-labeled polymer
shell (red channel). Examination of co-localization using the
Manders coeﬃcient[55] revealed values of M1 = 0.996 and M2 =
0.684 (channel 1: pGlu-b-pSar-AF647, channel 2: calcein). Based
on those ﬁndings, the polymer seems almost quantitatively co-
localized (∼99.6%) with the calcein signal (NP core) as illustrated
byMandersM1.MandersM2 reveals that approximately 68.4% of
the calcein signal are co-localized with the polymer. We therefore
concluded that the polymer remained attached to the NP surface
under serum conditions, especially since almost no isolated red
signal representing detached polymer was observed in themerge
channel.
2.4. Attachment of Targeting Ligands to the Polymer Shell
Enhances the NP Uptake
In order to improve NP uptake and selectivity toward cancer
cells, we introduced folate targeting, a concept initially developed
by Leamon and Low,[45] to our nanosystem. The folate receptor
is known to be overexpressed for many cancer types[46] and
the low dissociation constant (Kd approximately 0.1 nM for the
𝛼-isoform),[47] makes folate an attractive ligand for selective
cancer targeting.[48] A folate-modiﬁed block copolymer (pGlu-
b-pSar-FolA) was synthesized by coupling the azide-containing
pGlu-b-pSar to a DBCO-folic acid (DBCO-FolA)[49] building
block via SPAAC. Coating Zr-PMX@TMSP NPs with pGlu-
b-pSar-FolA (Figure S10, Supporting Information) as shown
in Figure 5 led to a nanoformulation with folic acid attached
to the polysarcosine terminus. Based on the polymer dose
titration experiment shown in Figure 4, which identiﬁed 25 µg
of polymer as suﬃcient for surface saturation of the used
amount of NPs, we initially evaluated by DLS how modifying
Zr-PMX@TMSP NPs with 25 µg pGlu-b-pSar containing dif-
ferent ratios of pGlu-b-pSar-FolA inﬂuenced NP size, PDI, and
zeta potential (Figure 5A). Compared to 0% pGlu-b-pSar-FolA, a
content of up to 75% pGlu-b-pSar-FolA did not notably inﬂuence
any of these parameters. Coating with 100% pGlu-b-pSar-FolA
led to aggregation, presumably as a result of the high con-
tent of hydrophobic ligands and the decreased electrostatic
repulsion.[50]
After conﬁrming folate receptor expression by ﬂow cytometry
(Figure S11, Supporting Information), the eﬀect of folate on NP
uptake was tested by confocal microscopy using adherent KB
(human cervix carcinoma, Figure 5C) and suspension L1210
(mouse lymphocytic leukemia, Figure 5D) cell lines. On both
cell lines, an enhanced uptake was observed for the folate-
containing nanopharmaceuticals compared to the untargeted
formulation. Flow cytometry analysis on KB cells (Figure 5B)
provided additional conﬁrmation of the increased uptake of
folate-targeted NPs compared to an untargeted control formula-
tion coated with pGlu-b-pSar only. A control sample with an equal
concentration of free calcein was also analyzed and did not show
any uptake. Importantly, this provided additional evidence that
the presented coordination NPs can mediate cellular uptake of
cargos that do not cross the cell membrane on their own. We also
developed a transferrin-functionalized formulation presented in
Figure 6 since the transferrin receptor is frequently
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Figure 4. Characterization of the pGlu-pSar coating. A) Structure of pGlu31-b-pSar160-N3; B) polymer dose titration and the inﬂuence on size, PDI,
and zeta potential by DLS (mean ± SD, n = 3); C) colloidal long-term stability of Zr-PMX@TMSP NPs (-pGlu31-b-pSar160-N3) and polymer-coated Zr-
PMX@TMSP NPs (+pGlu31-b-pSar160-N3) in HBG (mean ± SD, n = 3) or (D) PBS (mean ± SD, n = 3) at 37 °C; E) serum stability of the polymer coating
visualized by CLSM. Green channel, NP core labeled by coordinative integration of calcein. Red channel, polymer shell labeled with Alexa Fluor 647.
Yellow signal in the merged channel indicates co-localization of NP core and polymer shell. “All channels”: includes nuclei stained with DAPI (blue) and
actin stained with phalloidin-rhodamine (white).
overexpressed by cancer cells and undergoes rapid and eﬃcient
internalization upon ligand binding.[51] CoatingZr-PMX@TMSP
NPs with low amounts of 5 µg or 10 µg pGlu-b-pSar-Tf (Fig-
ure 6A) led to gradual increases in z-average and PDI, but
suitable NPs featuring a small z-average, narrow size distribu-
tion and neutral zeta potential could be obtained by coating with
25 µg pGlu-b-pSar-Tf (Figure 6B). After conﬁrming transferrin
receptor expression levels (Figure S11, Supporting Information),
confocal microscopy uptakes experiments with 1 h of incubation
revealed a transferrin targeting eﬀect on both KB (Figure 6C)
and A549 cells (Figure 6D). For both cell lines, the green calcein
signal representing labeled NP cores was more pronounced for
Tf-targeted NPs when compared to the untargeted NPs coated
with pGlu-b-pSar. Repeating the confocal microscopy experiment
with a reduced incubation time of 15 min in order to elucidate
the uptake kinetics (Figure S12, Supporting Information) led
to a similar result although the eﬀect of the transferrin target-
ing became less prominent due to the shorter NP exposure.
Quantitative evaluation by ﬂow cytometry (Figure 6E) also
showed a slight shift of the cell population toward higher calcein
ﬂuorescence at the early time point.
We also determined the cell killing potential of the NP for-
mulations using PMX sensitive L1210 and rather insensitive KB
cells. Initially, PMX dose–response (Figure S13 and S14, Sup-
porting Information) and incubation time studies (Figure S15
and S16, Supporting Information) were performed on both cell
lines to deﬁne the assay parameters and eﬀective concentration
ranges of PMX. Treatment of KB cells revealed preserved activ-
ity of Zr-PMX NPs compared to free PMX and a slight increase
in toxicity of folate- and transferrin-targeted formulations after
a short exposure time of 1 h (Figure 5E and 6F). A faster up-
take kinetic of the targeted nanoformulations compared to free
PMX could be a possible reason for the observation; the absence
of diﬀerent toxicities on KB cells after 72 h of incubation in-
dicates that potential beneﬁts of the targeted nanoformulations
can indeed rather be expected at early time points. Preserved ac-
tivity of PMX in the nanoformulations was also conﬁrmed for
the highly sensitive L1210 cells with 1 h of NP or drug expo-
sure time (Figure 5E). After 72 h, (Figure S16, Supporting Infor-
mation) Zr-PMX NPs even mediated an increased toxicity at the
low concentration of 1 nM (>60% reduced viability). However,
since PMX is a potent cytotoxic drug with high activity on L1210
cells, uptake kinetics do not seem to represent a major limiting
factor for this cell line and the advantage of targeted nanofor-
mulations can hardly be assessed under the static cell culture
conditions.
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Figure 5. Folate-targeting mediated by coating with pGlu-b-pSar-FolA. A) Polymer dose titration and inﬂuence on size, polydispersity, and zeta potential
by DLS (mean ± SD, n = 3); B) eﬀects of FolA-targeting on NP uptake by ﬂow cytometry; C) evaluation of NP uptake into KB; or (D) L1210 cells for
FolA-targeted and untargeted NPs by CLSM. Green, NP core labeled by coordinative integration of calcein. Red, actin stained with phalloidin-rhodamine.
Blue, nuclei stained with DAPI. E) Cell viability studies with KB (top) and L1210 (bottom) by MTT-assay (mean ± SD, n = 5). Cells were treated with NPs
or free drug for 1 h, then the medium was changed and the readout took place after 72 h. PMX content of NPs was quantiﬁed by HPLC and the dosing
adjusted accordingly. Statistical analysis was performed by two-way ANOVA, 𝛼 = 0.05.
3. Conclusions
In sum, a novel approach for the assembly and subsequent core-
shell functionalization of a drug carrier with a very high loading
capacity, tunable stabilization against serum, surface shielding
and the option for receptor targeting is presented. The drug-
containing core consists of PMX and Zr ions which assemble
into nanocolloids via Lewis acid–base interactions. The absence
of crystallinity suggests that the mesoporous Zr-PMX NPs can
rather be classiﬁed as amorphous coordination polymers. Since
PMX displays a high binding aﬃnity toward serum protein, the
particles disassemble rapidly in a serum-containing environment
and require a thin TMSP-based silica shell for stabilization and
simultaneous control of drug release. A pGlu-b-pSar-N3 block-
copolymer represents the outermost layer of the delivery system,
mediates surface shielding, highly eﬃcient colloidal stabiliza-
tion and enables modiﬁcation with uptake-enhancing receptor
ligands as shown for folate and transferrin. In vitro evaluations
conﬁrmed the maintained pharmacological activity of PMX on
KB human cervix carcinoma and L1210 mouse lymphocytic
leukemia cells and the cellular uptake of otherwise impermeable
coencapsulated calcein. The presented concept is considered
to be an example of an envisioned “minimalist design” of
nanopharmaceuticals with a very high drug-to-carrier material
ratio meant to minimize patient exposure to inactive carrier
materials.
4. Experimental Section
Materials and Reagents: Pemetrexed disodium heptahydrate
(PHR1596), zirconium(IV)chloride, transferrin from human plasma,
DBCO-PEG4-NHS, N
1-(3-trimethoxysilylpropyl)diethylenetriamine,
DBCO-PEG4-NHS, and calcein were obtained from Sigma–Aldrich
(Germany). Ethanol absolute and HCl 37% were obtained from VWR
chemicals. DBCO-FolA used to generate pGlu-pSar-FolA was synthesized
in house as reported earlier.[49] HEPES was purchased from Biomol,
formic acid (≥ 99.5%) was bought from Fluka (Buchs, Switzerland),
DBCO-Alexaﬂuor647 was purchased from Jena Biosciences (Jena,
Adv. Therap. 2019, 2, 1900120 1900120 (8 of 14) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advtherap.com
Figure 6. Transferrin targeting mediated by coating with pGlu-b-pSar-Tf. A) Structure of pGlu-b-pSar-Tf; B) polymer dose titration and inﬂuence on size,
polydispersity, and zeta potential by DLS (mean ± SD, n = 3); C) evaluation of NP uptake into KB; or (D) A549 cells for Tf-targeted and untargeted NPs
by CLSM. Green, NP core labeled by coordinative integration of calcein. Red, actin stained with phalloidin-rhodamine. Blue, nuclei stained with DAPI. E)
Eﬀects of Tf-targeting on NP uptake by ﬂow cytometry and F) cell viability studies with KB by MTT-assay (mean ± SD, n = 5). Cells were treated with NP
or free drug for 1 h, then the medium was changed and the readout took place after 72 h. PMX content of NPs was quantiﬁed by HPLC and the dosing
adjusted accordingly. Statistical analysis was performed by two-way ANOVA, 𝛼 = 0.05.
Germany),FBS and cell culture mediums were bought from Life Tech-
nologies (USA) or Sigma-Aldrich. HBG buﬀer pH 7.4 containing 20 mM
HEPES, 5% glucose (w/v), and 20 mM PBS pH 7.4 were prepared
in-house. All used water was generated utilizing the Milli-Q Academic
A-10 system from Millipore (Billerica, USA).
Synthesis of Zr-PMX NPs: A mixture of 416 µL 10 mM ZrCl4 (1 eq.,
4.16 µmol, freshly dissolved in bidistilled water), 50 µL 1 M HCl and
48.5 µL formic acid (100 eq.) was prepared in a 50 mL falcon tube
and stirred at medium speed using a magnetic stirrer (solution I). In a
separate 5 mL tube, 488 µL 15 mg mL−1 pemetrexed disodium heptahy-
drate (3 eq., 12.48 µmol, dissolved in bidistilled water) was mixed with
3 mL EtOH absolute (solution II). Solution II was then quickly added to
solution I while stirring. The mixture was further stirred at medium speed
for 45 min. Afterward, the reaction batch was split into three 1.5 mL
polystyrene microcentrifuge tubes and centrifuged (Eppendorf tabletop
centrifuge,14 000 rpm, 1 min, Eppendorf GmbH, Hamburg, Germany).
The supernatants were removed and the three pellets were uniﬁed in
1 mL fresh EtOH absolute. The concentrated NP stock solution was then
washed an additional two times with EtOH absolute (1 mL EtOH absolute
and 1 min @ 14 000 rpm centrifugation per washing step). The washed
NPs were redispersed in 1 mL EtOH absolute by gentle pipetting and sub-
sequently sonicated for 5 min (20 °C, power 9) using a VWR USC THD/HF
Ultrasonic Cleaner (VWR International GmbH, Darmstadt, Germany).
Synthesis of Zr-Calcein-PMXNPs: Zr-PMXNPs containing calcein were
prepared identically to Zr-PMX NPs with the exception of solution II addi-
tionally containing 17.85 µM calcein (12.5 µL 5 mM calcein were added to
solution II prior to mixing solutions I and II).
Dynamic Light Scattering: Size and zeta-potential measurements
were performed at a backscattering angle of 173° using the Nano Series
Nano-ZS Zetasizer equipped with DTS-1070 folded capillary cuvettes
(Malvern Instruments, Malvern, Worcestershire, United Kingdom). For
sizemeasurements, an equilibration time of 0 s was set and the attenuator
was adjusted automatically. Measurements in HEPES-buﬀered glucose
were performed at 25 °C with a solvent refractive index of 1.330 whereas a
temperature of 20 °C and a solvent refractive index of 1.3617 were used for
EtOH. Each sample was measured three times with at least six subruns
each and z-averages, PDIs, and zeta potentials were reported as mean
± standard deviation. Zeta potential measurements were carried out in
HEPES-buﬀered glucose as triplicates with 10–15 subruns each and the
actual zeta potential values were calculated by the zetasizer software by
applying the Smoluchowski equation.
Determination of Zirconium Content by ICP-AES: A total of 1 mL
Zr-PMX NPs in EtOH was transferred to a weighed polystyrene micro-
centrifuge tube, centrifuged (1 min, 14 000 rpm, Eppendorf tabletop
centrifuge) and the supernatant was carefully discarded. The NP pellet
was then dried under high vacuum for approximately 24 h followed by
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approximately 4 h drying at 90 °C. Next, the Eppendorf caps were weighed
again and the dried NPs were digested in 69% (v/v) HNO3 for trace
analysis (Aristar, VWR) and subsequently diluted with bidistilled water
to 3% (v/v) HNO3. The samples were then analyzed for their Zirconium
content by ICP-AES (CCD simultaneous ICP AES Vista RL by Agilent,
suction time 35 s, stabilization time 45 s, power 1.25 kW). The following
wavelengths were determined: 257.47, 327.307, 339.198, 343.823, and
349.619. Utilizing this method, three independent samples were prepared
and analyzed and the zirconium content was reported as average mass
percentage ± standard deviation.
Determination of PMX Content by HPLC: Zr-PMX NPs in EtOH were
synthesized as described above. A total of 200 µL of the synthesized Zr-
PMX NPs in EtOH was then mixed with 1 mL 500 mM EDTA pH 8.2 and
300 µL bidistilled water. Three independent samples were prepared and
incubated for 72 h at 25 °C under constant shaking (500 rpm, Eppen-
dorf tabletop shaker, Eppendorf GmbH, Hamburg, Germany). In order to
avoid EDTA precipitation under acidic conditions, the lysed NPs were sub-
sequently diluted with an equal volume of 0.1% (v/v) triﬂuoroacetic acid
(TFA) in bidistilled water and the PMX released from the NPs was then
quantiﬁed by HPLC (Hitachi Chromaster, YMC RP-18 column, 50 µL in-
jection volume, PMX retention time 10.847 min, monitoring @ 225 nm,
solvents bidistilled water + 0.1% TFA, HPLC-grade acetonitrile (ACN) +
0.1%TFA (0–2.5min: 1%ACN+ 0.1% TFA, 2.5–11min: increase to 41.4%,
11–12 min: increase to 100%, 12–14 min: wash with 100%). Using a PMX
calibration curve and the PMX molecular weight of 427.411 g mol−1, the
mass of PMX present in each sample was calculated. To obtain the drug
loading of PMXwithin theNP, the total mass of NP present in each sample
was determined by transferring 1 mL Zr-PMX NPs in EtOH to a weighed
1.5 mL polystyrene microcentrifuge tube, centrifuging (1 min, 14 000 rpm,
Eppendorf tabletop centrifuge) and removing the supernatant very care-
fully to avoid loss of material. The NP pellet was then dried under high
vacuum for approximately 48 h followed by approximately 4 h drying at 90
°C. The average of three mass determinations was then used to calculate
the mass of NP present in each HPLC sample. The fraction of PMX in the
NP (w/w) was subsequently calculated according to the following formula:
[µg PMX in the HPLC sample/µg NP in the HPLC sample] × 100%.
Scanning Electron Microscopy (SEM): The respective NP stock solu-
tions in EtOH were concentrated approximately tenfold (by centrifugation
and redispersion in a smaller volume of EtOH) and subsequently spotted
onto a hydrophobic SEM sample carrier. After drying overnight in a dust
protected environment, the samples were sputtered with carbon (three cy-
cles of carbon vacuum deposition) and their morphology was then charac-
terized using a Dual beam FEI Helios G3 UC SEM operated at 3 kV. Parti-
cle sizes were determined by recording high-resolution images, correcting
them for contrast and brightness and subsequently measuring 100 par-
ticles using the ImageJ software (version 1.50i). The obtained sizes were
reported in nanometers as average ± standard deviation. The elemental
composition was analyzed during SEM measurements by energy disper-
sive X-ray spectroscopy (EDX) using an Oxford Instruments X-Max N80
device.
X-ray Diﬀraction: XRD was measured with a Stadi MP STOE trans-
mission diﬀractometer system with Cu K𝛼1 radiation (𝜆 = 1.54060 Å)
and a Ge(111) single crystal monochromator. All samples were pre-
pared by ﬁxating the dried samples between two polymer foils. Diﬀrac-
tion patterns were recorded with a DECTRIS solid-state strip detector
MYTHEN 1K in a transmission setup derived from Debye–Scherrer ge-
ometry using a step size of 4.71° and a counting time of 120 s per step.
For data analysis, the WinXPOW RawDat v3.0.2.5 software package was
used.
BET Sorption Measurements: The nitrogen sorption isotherm was
measured at 77 K with a Quantachrome Autosorb-1 iQ. Approximately
7.3 mg dried NPs was degassed at 60 °C under high vacuum for 38 h prior
to the measurement. Evaluation of the sorption data was carried out us-
ing the ASiQwinTM software (Version 3.0, Quantachrome Instruments).
BET surface areas were calculated employing the linearized form of the
BET equation. With a relative pressure range between 0.15 and 0.27, this
resulted in a correlation coeﬃcient >0.999 with a positive C constant. The
adsorption isotherm was then used to calculate the pore size distribution
by employing the quenched solid density functional theory (QSDFT, N2 at
77 K on carbon, cylindrical pores adsorption branch).
Thermogravimetric Analysis: Thermogravimetric analysis was carried
out with a thermomicrobalance (Netzsch, STA 449 C Jupiter) by applying
a heating rate of 10 °C min−1 up to 900 °C. A total of 7.425 mg of ma-
terial was heated under synthetic air (N2/O2 mixture) with a ﬂow rate of
25 mL min−1. For data evaluation, the Proteus—Thermal Analysis (v.4.3)
software was used.
TMSP-coating of Zr-PMX NPs: A mixture of 1 mL EtOH absolute and
3 µL TMSP was prepared in a 50 mL falcon tube and stirred at low to
medium speed with a magnetic stirrer. In a separate vial, 400 µL Zr-PMX-
NPs in EtOH were prediluted with 2 mL ethanol absolute and brieﬂy vor-
texed. The prediluted Zr-PMX NPs were then added dropwise to the di-
luted TMSP solution within approximately 2 min and stirred for 5 min at
low to medium speed. After 5 min, the polymerization process was ini-
tiated by addition of 60 µL 5M HCl. The tube was then stirred at low to
medium speed for 3 h. Afterward, the reaction batch was split into three
1.5 mL polystyrenemicrocentrifuge tubes, centrifuged (1min, 14 000 rpm,
Eppendorf tabletop centrifuge) and the three pellets were uniﬁed in 1 mL
fresh EtOH absolute. The sample was washed two more times with EtOH
absolute (1 mL, 1 min@14 000 rpm, Eppendorf tabletop centrifuge). After
the ﬁnal washing step, the pellet was redispersed in 1 mL EtOH absolute
and sonicated for 5 min (20 °C, power9) using the VWR USC THD/HF
Ultrasonic Cleaner (VWR International GmbH, Darmstadt, Germany). Zr-
Calcein-PMX NPs were coated with TMSP using the same protocol.
Serum Stability of Zr-PMX@TMSP NPs: For each sample, 1 mL of Zr-
Calcein-PMX@TMSP NPs in EtOH was centrifuged (1 min, 14 000 rpm,
Eppendorf tabletop centrifuge) and the supernatant was removed care-
fully to avoid loss of material. The pellet was then redispersed in 1mL 10%
(v/v) fetal bovine serum and subsequently incubated at 37 °C for 30 min.
After the incubation, the samples were centrifuged (5 min, 14 000 rpm,
Eppendorf tabletop centrifuge) and 100 µL of supernatant was diluted
with 100 µL 0.1% (v/v) TFA in bidistilled water. The amount of released
PMX present in the supernatant was then quantiﬁed by HPLC using a
sample volume of 100 µL and the instrumentation described in section
“Determination of PMX Content by HPLC.” To obtain 100% release
values to normalize to, a triplicate with respective equal amounts of NP
was centrifuged (1 min, 14 000 rpm, Eppendorf tabletop centrifuge), the
supernatants were carefully discarded and the pellets were redispersed in
1 mL lysis buﬀer (500 mM EDTA pH 8.2) and incubated approximately 72
h (37 °C, 500 rpm). The set was then quantiﬁed by HPLC and the average
of the determined PMX content was used as 100% value. The amount
of released PMX for the serum-incubated samples was then calculated
according to the following formula: [PMX in supernatant/PMX in lysis
sample] * 100%. For each time point, a set of independent triplicates was
prepared and analyzed and the percentage of released PMX was reported
as average ± standard deviation.
Synthesis of pGlu31-b-pSar160-N3: All monomers were prepared ac-
cording to the Fuchs–Farthing method with diphosgene as phosgene
source and puriﬁed by recrystallization (Glu(OtBu)-NCA) or sublimation
(SarNCA) as reported previously.[40,52] The synthetic pathway to azide-
modiﬁed poly(l-glutamic acid)-block-poly(sarcosine) was adapted and
modiﬁed from Yoo et al. and Schäfer et al.[53]
Brieﬂy, poly(𝛾-tert-butyl-l-glutamic acid)-block-poly(sarcosine) (pGlu
(OtBu)-b-pSar) was prepared via sequential N-carboxyanhydride (NCA)
polymerization initiated by neopentylamine. A total of 407.6 mg
(1.78 mmol; 31 eq.) of 𝛾-tert-butyl-l-glutamic acid (Glu(OtBu))-NCA was
weighed into a pre-dried Schlenk-ﬂask, dissolved in mixture of 1:1 THF
and DMF (both dried and freshly distilled) at a concentration of 100 g L−1,
cooled to 0 °C, and a solution of neopentylamine (5.0 mg; 57.4 µmol; 1.0
eq.) in 0.5 mL of DMF was added. After completed Glu(OtBu)-NCA con-
sumption, as monitored by FT-IR spectroscopy, a solution of sarcosine-
NCA (1.06 g; 9.17 mmol; 160 eq.) in 5.0 mL of DMF was added and the
polymerization was continued at 10 °C. For azide end-group modiﬁcation,
pentaﬂuorphenyl-4-azidobutanoate (33.9 mg; 0.115 mmol, 2.0 eq.) and
N,N-diisopropylethylamine (DIPEA) (53 µL; 0.304 mmol; 5.0 eq.) were
added and the solution was stirred at room temperature for 18 h. To re-
act residual-free end groups, acetic anhydride (54 µL; 0.57 mmol; 10 eq.)
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and DIPEA (195 µL; 1.11 mmol; 20 eq.) were added and the solution was
stirred for 1 day. The obtained block copolymer was puriﬁed by repetitive
(3×) precipitation/centrifugation (4500 rpm, 15 min, 4 °C) into a mixture
of n-hexane and diethyl ether (2:1). The product (pGlu (OtBu)31-b-pSar160-
N3) was dried in vacuo and obtained as a white powder (846 mg, 86%).
1H NMR: pGlu (OtBu)n-b-pSarm-N3 (400 MHz, CD2Cl2), 𝛿 [ppm] =
8.45−8.11 (22 H, br, −NH−CO−CH−), 4.40−3.82 (323 H (1n + 2m),
br, −CO−CH−NH + −CO−CH2−NCH3−), 3.20−2.80 (454 H (3m), m,
−NCH3−CO−), 2.66−1.70 (140 H, m, −CH2−CH2−), 1.53−1.36 (285 H,
s + br,−O−C(CH3)3), 0.94−0.83 (9 H, br CH2−C(CH3)3). HFIP-GPC: Mn
= 39.5 kg mol−1, Mw = 45.4 kg mol−1; Ð = 1.15.
For deprotection, 800 mg of pGlu (OtBu)31-b-pSar160-N3 was dissolved
in 16 mL of a mixture of 45:45:5:5 DCM/TFA/TIPS/water over 3 h in
a Schlenk-ﬂask with constant stirring. Polymers were precipitated into
ether, centrifuged in sealed Falcon tubes and the precipitate was dia-
lyzed against aqueousNaHCO3 andwater, followed by lyophilization (yield
80%). Successful deprotection was veriﬁed by 1H NMR.
1H NMR: pGlu (COOH)n-b-pSarm-N3 (400 MHz, D2O), 𝛿 [ppm] =
4.50−4.00 (490 H, (1n + 2m), m, HN−CH2−CO + HN−CH−CO),
3.30−2.72 (669 H (3m), mNCH3), 2.33−1.70 (195 H (2n), m, CH2−CH2),
0.77-0.71 (9H, s, −C(CH3)3). HFIP-GPC: Mn = 29.4 kg mol−1, Mw =
35.1 kg mol−1; Ð = 1.19.
HFIP-GPC:
Synthesis and Puriﬁcation of pGlu31-b-pSar160-Folate: Pglu31-Psar160-
FolA was synthesized by reacting pGlu31-b-pSar160-N3 with a DBCO-
Folate conjugate, referred to here as DBCO-FolA, (folic acid-lysine-DBCO;
gamma-COOH of folic acid coupled to alpha-amine of lysine, epsilon-
amine of lysine coupled to DBCO-carboxylic acid).[49] A total of 3 mg
pGlu31-b-pSar160-N3 (1 eq., 189.9 nmol) was dissolved in 168 µL 1 mg
mL−1 DBCO-FolA (1 eq, 189.9 nmol) inHBG (20mM, pH7.4). Themixture
was incubated overnight and dialysed for 2 days at 4 °C against Millipore-
water. A Spectra/Por prewetted RC tubing dialysismembranewith amolec-
ular weight cutoﬀ of 2 kD was used and the water was changed once after
approximately 24 h. The puriﬁed compound was snap frozen in liquid ni-
trogen, freeze-dried (Christ Alpha 2–4 LD plus, Martin Christ, Gefriertrock-
nungsanlagen GmbH, Osterode, Germany) and dissolved in bidistilled
water at 1 mg mL−1.
Synthesis and Puriﬁcation of pGlu31-b-pSar160-Transferrin: Transferrin
from human plasma (50 mg, 1 eq., 0.67 µmol) was dissolved in 1 mL
HEPES buﬀer (20 mM, pH 7.4). DBCO-PEG4-NHS ester was dissolved
in DMSO (20 mgmL−1) and 43.5 µL (0.87 mg, 2 eq., 1.3 µmol) was added
to the transferrin solution. The reaction mixture was incubated for 3 h at
room temperature under gentle shaking (25 °C, 400 rpm). The solution
was then puriﬁed by size exclusion chromatography using an ÄKTA puri-
ﬁer system (GEHealthcare), a Sephadex G25 super ﬁne-size exclusion col-
umn and HEPES buﬀer (20 mM, pH 7.4) as a mobile phase. The collected
fractions containing the DBCO-modiﬁed transferrin were pooled and the
protein concentrationwas determined by Bradford assay.[54] By pooling the
fractions, 4.75 mL DBCO-PEG4-transferrin with a concentration of 105 µM
corresponding to a total yield of approximately 79% was obtained. Next,
pGlu31-b-pSar160-N3 (3 mg, 1.1 eq., 189.9 nmol) was dissolved in 1.81 mL
of the obtained DBCO-PEG4-transferrin (1 eq., 209 nmol) and the mixture
was incubated overnight. The resulting transferrin-modiﬁed polymer was
diluted with HEPES to a ﬁnal concentration of 1 mg mL−1, used without
further puriﬁcation and stored at 4 °C.
Synthesis and Puriﬁcation of pGlu31-b-pSar160-AF647: DBCO-
AlexaFluor647 (Jena Bioscience GmbH, Jena, Germany) was dissolved
in DMSO at 1 mg mL−1. A total of 455 µL of the dissolved DBCO-
Alexaﬂuor647 (1.2 eq., 403 nmol) was then used to dissolve 5.3 mg
pGlu31-b-pSar160-N3 (1 eq., 335 nmol). The obtained mixture was then
incubated overnight in an Eppendorf tabletop shaker (25 °C, 400 rpm). On
the next morning, the product was dialyzed for about 48 h at 4 °C against
bidistilled water. Prior to adding the reaction batch to the dialysis mem-
brane (Spectra/Por prewetted RC Tubing, MWCO 2 kD), the membrane
was rinsed with bidistilled water to remove the azide antifouling agent
and bidistilled water was then added to the sample to reduce the DMSO
content to approximately 20% v/v as a precaution in order to safeguard
membrane integrity. During the dialysis step, the water was changed once
after approximately 12 h, minor precipitation of blue product within the
dialysis bag was observed. After dialysis, the sample was snap frozen in
liquid nitrogen and freeze-dried over 2 days (Christ Alpha 2–4 LD plus,
Martin Christ, Gefriertrocknungsanlagen GmbH, Osterode, Germany)
and dissolved in bidistilled water at a ﬁnal concentration of 1 mg mL−1.
Uptake Experiments by CLSM: The respective cells were seeded in
eight well-chamber slides (Thermo Fisher Scientiﬁc, 20.000 cells in 300 µL
medium per well) 1 day prior to recording the images and cultured at 37 °C
and 5% CO2. On the day of the experiment, the medium was exchanged
for 240 µL of fresh medium. The NPs were added in 60 µL HBG per well.
After 1 h of incubation, the treatment solutions were replaced with fresh
medium and the cells were incubated for additional 2 h at 37 °C and 5%
CO2. Cells were then ﬁxated with 4% paraformaldehyde in PBS (30 min in-
cubation, room temperature). After ﬁxating the cells, each well was washed
once more with 400 µL PBS. Nuclei were stained with DAPI (2 µg mL−1)
and F-Actin was labeled with phalloidin-rhodamine (1 µg mL−1). After 30
min of light-protected incubation at room temperature, the staining mix-
ture was removed and replaced with 300 µL PBS per well. Images were
then recorded on a Leica-TCS-SP8 confocal laser scanning microscope
equipped with an HC PL APO 63 × 1.4 objective. DAPI emission was
recorded at 460 nm and calcein at 530 nm. All images were processed
utilizing the LAS X software from Leica.
pGlu31-b-pSar160-N3 Coating of Zr-PMX@TMSP NPs: pGlu31-b-
pSar160-N3 was prepared as an aqueous 1 mg mL
−1 stock solution. For
the dose titration studies, x µL polymer corresponding to x µg polymer
was added to a 5 mL polystyrene tube and stirred at medium speed. Next,
ethanolic Zr-PMX@TMSP NPs were centrifuged (1 min, 14 000 rpm,
Eppendorf tabletop centrifuge). The supernatant was carefully removed
and the particles were redispersed in an equal volume of HBG (20 mM,
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pH 7.4). The particles in HBG were then sonicated for 1 min. Next, 500 µL
of Zr-PMX@TMSP NPs in HBG were added dropwise to the stirred
polymer solution over approximately 2 min. The solution was stirred for
additional 3 min and the obtained polymer-coated Zr-PMX@TMSP NPs
were sonicated for 1 min (power 9, 20 °C) using the VWR USC THD/HF
Ultrasonic Cleaner (VWR International GmbH, Darmstadt, Germany).
pGlu31-b-pSar160-FolA Coating of Zr-PMX@TMSP NPs: To obtain
folate-targeted Zr-PMX@TMSP NPs, a mixture of 1 mg mL−1 Pglu31-
Psar160-N3 and 1 mg mL
−1 pGlu31-b-pSar160-FolA was prepared in a
5 mL Eppendorf tube stirred at medium speed. A total of 500 µL of Zr-
PMX@TMSP NPs in HBG was added dropwise to the stirred polymer
solution over approximately 2 min. The solution was stirred for an addi-
tional 3 min and the obtained polymer-coated Zr-PMX@TMSP NPs were
sonicated for 1 min (power 9, 20 °C) using the VWR USC THD/HF Ul-
trasonic Cleaner (VWR International GmbH, Darmstadt, Germany). For
the dose titration experiment, a total of 25 µL polymer containing various
percentages pGlu31-b-pSar160-FolA was used. For the uptake experiments
by confocal microscopy and the MTT assay, 500 µL of Zr-PMX@TMSP
NPs in HBG was coated with a ﬁxed amount of 25 µg polymer containing
25% folate-modiﬁed polymer (6.25 µL 1 mg mL−1 pGlu31-b-pSar160-FolA
+ 18.75 µL pGlu31-b-pSar160-N3) as described above.
pGlu31-b-pSar160-Transferrin Coating of Zr-PMX@TMSP NPs: To ob-
tain transferrin-targeted Zr-PMX@TMSP NPs x µL 1 mg mL−1 pGlu31-
b-pSar160-transferrin (nomalized to polymer content) was prepared in a
5 mL polystyrene microcentrifuge tube stirred at medium speed. A total of
500 µL of Zr-PMX@TMSP NPs in HBG was added dropwise to the stirred
polymer solution over approximately 2 min. The solution was stirred for
another 3min and the obtained polymer-coated Zr-PMX@TMSPNPswere
sonicated for 1 min (power 9, 20 °C) using the VWR USC THD/HF Ultra-
sonic Cleaner (VWR International GmbH, Darmstadt, Germany). For the
dose titration experiment, various amounts (0– 50 µL) pGlu31-b-pSar160-
transferrin were used. For the uptake experiments by confocal microscopy,
500 µL of Zr-PMX@TMSP NPs in HBG was coated with a ﬁxed amount of
25 µg pGlu31-b-pSar160-transferrin as described above.
Colloidal Stability Studies of Zr-PMX@TMSP-NPs ± pGlu31-b-pSar160-
N3: For the HBG stability experiment, 500 µL Zr-PMX@TMSP NPs in
HBG were coated with 25 µg pGlu31-b-pSar160-N3 as described above and
incubated using an Eppendorf tabletop shaker (37 °C, 400 rpm). Every 24
h, 75 µL sample was drawn, diluted with 645 µL HBG and size, PDI and
zeta-potential were determined by DLS. For the PBS stability experiment,
Zr-PMX@TMSP-NPs were coated with 25 µg pGglu31-b-pSar160-N3 and
incubated as described above. Then, 200 µL of the coated NPs in HBG
were added to 800 µL PBS (20 mM, pH 7.4). Every 24 h, 180 µL sample
was withdrawn, diluted with 540 µL PBS and then the size, PDI, and zeta
potential were determined as described earlier.
Serum Stability of the Polymer Coating: In a 5 mL polystyrene micro-
centrifuge tube, 25 µL pGlu31-b-pSar160-AF647 was stirred at medium
speed. A total of 500 µL Zr-PMX@TMSP NPs in HBG was added
dropwise to the stirred polymer solution over approximately 2 min. The
solution was stirred for another 3 min and the obtained polymer-coated
Zr-PMX@TMSP NPs were sonicated for 1 min (power 9, 20 °C) using the
VWR USC THD/HF Ultrasonic Cleaner (VWR International GmbH, Darm-
stadt, Germany). One day prior to recording the images, KB cells were
seeded in eight well-chamber slides (Thermo Fisher Scientiﬁc, 20 000 cells
in 300 µL medium per well) and cultured at 37 °C and 5% CO2. On the day
of the experiment, the medium was removed, replaced with 240 µL fresh
medium and 60 µL NPs dispersed in HBG were added. After 2 h of incu-
bation at 37 °C and 5% CO2, each well was emptied by aspiration, supple-
mented with fresh medium, and incubated for another 2 h. The cells were
then ﬁxated with 4% paraformaldehyde in PBS (30 min incubation, room
temperature). After ﬁxating the cells, each well was washed once more
with 400 µL PBS. Cell nuclei were then stained with DAPI (2 µg mL−1) and
F-Actin was labeled with phalloidin-rhodamine (1 µg mL−1). After 30 min
of incubation (room temperature, light protection), the staining mixture
was removed and replaced with 300 µL PBS per well. Images were gen-
erated on a Leica-TCS-SP8 confocal laser scanning microscope equipped
with an HC PL APO 63 × 1.4 objective. DAPI emission was recorded at
460 nm, calcein at 530 nm, rhodamine at 580 nm, and Alexaﬂuor647 at
667 nm. All images were processed with the LAS X software from Leica.
Evaluation of Toxicity by MTT-assay (KB Adherent Cells): A total of
5 000 KB cells/well were seeded in 96-well plates (Corning® Costar,
Sigma–Aldrich, Germany) 1 day prior to the experiment. The respective
amount of formulation to be tested was prepared in HBG pH 7.4 at a
ﬁvefold concentration. For each well, 100 µL of treatment solution was
prepared by mixing 20 µL formulation in HBG with 80 µL medium. After
24 h seeding the cells, the medium was aspirated and replaced with
100 µL treatment solution. For each formulation and concentration, an
independent quintuplicate of ﬁve wells was treated. After addition of
the treatment, the cells were incubated for the indicated duration at 37
°C and 5% CO2. Afterward, the wells were aspirated and replaced with
fresh medium. After 72 h addition of the sample solutions, 10 µL MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5 mg
mL−1) resulting in a ﬁnal concentration of 0.5 mg mL−1 was added to
each well. The plates were then incubated for 2 h at 37 °C under mild
shaking. Unreacted dye and medium were subsequently aspirated and
the 96-well plates frozen at −80 °C for approximately 2 h. In order to fully
dissolve the purple formazan product, 100 µL DMSO was added to each
well. The plates were then incubated under agitation for another 30 min.
By measuring the absorbance at 590 nm taken together with a background
correction at 630 nm using a microplate reader (TecanSpectraﬂuor Plus,
Tecan, Switzerland), the absorption of each well was quantiﬁed. The
relative cell viability (%) related to control wells treated with 20 µL HBG
(pH 7.4) was then calculated as ([A] test/[A] control) × 100%.
Evaluation of Toxicity by MTT-assay (L1210 Suspension Cells): L1210
cells were withdrawn from their culture ﬂask, centrifuged (1500 rpm,
5 min), washed, resuspended in folate-free medium and cultured for
24 h at 37 °C and 5% CO2. Afterward, the cell density was determined
and adjusted to 125 000 cells mL-1. Treatment solutions in HBG buﬀer
were prepared at ﬁvefold their intended ﬁnal concentration. A total of
480 µL cell suspension (125 000 cells mL−1) was then mixed with 120 µL
respective treatment solution prepared at ﬁvefold concentration. The
obtained 600 µL cell suspension now containing the treatment at the
ﬁnal onefold concentration was then transferred to ﬁve adjacent wells of
a 96-well plate(100 µL corresponding to 10 000 L1210 cells were added
to each well). The cells were then cultured for the indicated duration at
37 °C and 5% CO2. For the 1 + 71 h incubation, cells were washed after
1 h by centrifuging (1500 rpm, 5 min) and replacing 50 µL of supernatant
with fresh folate-free medium. This step was performed twice. After 72 h
addition of the sample solutions, 100 µL of lysis buﬀer (10 mM HCl, 10%
w/v sodiumdodecylsulfate) was added to each well. The plates were then
incubated for 2 h (37 °C, 5% CO2). Absorption values were then deter-
mined at 590 nm taken together with a background correction at 630 nm
using a microplate reader (TecanSpectraﬂuor Plus, Tecan, Switzerland).
The relative cell viability (%) related to control wells treated with 20 µL
HBG (pH 7.4) was then calculated as ([A] test/[A] control) × 100%.
NP Uptake Studies by Flow Cytometry: One day before performing the
experiment, KB cells were seeded in a 24-well plate. Each well contained
60 000 cells dispersed in 1 mL medium. On the next day, the medium was
removed and replaced with 400 µL fresh medium. Next, 100 µL function-
alized NPs in HBG were added to each well. After 1 h, the medium was
removed by aspiration and each well was washed with 1 mL of PBS fol-
lowed by trypsinization (5 min, 37 °C) with 200 µL of trypsin/EDTA. A
total of 400 µL medium was added to each well and the cells were cen-
trifuged (5 min, 1500 rpm, room temperature). In order to have enough
cells for analysis, two independent wells per condition were pooled. The
supernatant was removed and the cells were resuspended in 700 µL FACS-
buﬀer (10% FBS in PBS) and stored on ice. Directly prior to analysis, 2 µL
DAPI (1 mg mL−1) was added to each vial. Data were recorded utilizing
the LSR Fortessa ﬂow cytometer (BD Biosciences, Eysins, Switzerland).
Gating and data analysis were performed with the FlowJo 7.6.5 ﬂow cy-
tometry analysis software. Initially, cells were gated by forward/sideward
scatter and pulse width in order to exclude cell aggregates. Dead cells were
subsequently excluded using DAPI and only isolated viable cells were eval-
uated. Approximately 10 000 gated cells per sample were collected. The
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threshold level for NP binding was determined based on the ﬂuorescence
of HBG-treated control wells.
Statistical Analysis: If not stated otherwise within themanuscript or re-
spective methods part, data are presented as mean ± standard deviation.
Triplicates were analyzed for DLS measurements, ICP–AES, and PMX con-
tent by HPLC. For SEM, the as-obtained images were normalized to the
scale bar and the size of 100 particles was subsequently analyzed. In ﬂow
cytometry experiments, a minimum of 10 000 gated cells were evaluated
per condition. For the PMX content determination by HPLC, a PMX cali-
bration curve (six data points between 0 nmol and 5 nmol) was recorded
(R2 = 0.9976). MTT experiments were performed in quintuplicates and the
data were analyzed by two-way ANOVA utilizing GraphPad Prism version
6.01. Testing was performed with 𝛼 = 0.05 and n = 5. After performing
the analysis, stars were assigned according to the p-values: *for p ≤ 0.05,
**for p ≤ 0.01, *** for p ≤ 0.001, and **** for p ≤ 0.0001.
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